Work

Abstract PS2-11-06: Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trial

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps2-11-06

Authors: T. Bui, D. M. Wolf, R. W. Sayaman, C. Yau, A. M. Glas, J. Coppé, L. Brown Swigart, G. L. Hirst, P. R. Pohlmann, L. Pusztai, J. M. Rosenbluth, L. J. Esserman, E. F. Petricoin, L. J. Van 't Veer

Institutions: University of California, San Francisco, Quantum Leap Healthcare Collaborative, The University of Texas MD Anderson Cancer Center, Yale Cancer Center, Yale University, George Mason University

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129519504

Cites:

Cited by:

Related to: